Abstract.
Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension. As vasopressin receptors are found in many different tissues, vasopressin antagonists may benefit the treatment of disorders such as cerebral ischaemia and stroke, Raynaud’s disease, dysmenorrhoea and tocolytic treatment. V1b selective vasopressin antagonists are discussed in terms of their usefulness in the treatment of emotional and psychiatric disorders. The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. The V1a/V2 non-selective vasopressin antagonist conivaptan is the first vaptan which is approved by the FDA for the treatment of euvolaemic hyponatraemia.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 3 February 2006; received after revision 16 March 2006; accepted 26 April 2006
Rights and permissions
About this article
Cite this article
Lemmens-Gruber, R., Kamyar, M. Vasopressin antagonists. Cell. Mol. Life Sci. 63, 1766 (2006). https://doi.org/10.1007/s00018-006-6054-2
Published:
DOI: https://doi.org/10.1007/s00018-006-6054-2